SCHEMBL375079

SCHEMBL375079

FC(F)(F)Oc1ccccc1CNC1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.51
PDCD1 Q15116 1/20 0.46
CD274 Q9NZQ7 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41
EPHX2 P34913 6/20 0.41
CYP2C9 P11712 3/20 0.41
CYP2J2 P51589 3/20 0.41
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
BACE1 P56817 1/20 0.40
ADRA2A P08913 1/20 0.40
MCHR1 Q99705 1/20 0.40
KCNN3 Q9UGI6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16269143 0.80 CYP2D6 (0.49) TACR1PDCD1CD274KMT2AEPHX2
SCHEMBL375224 0.75 OPRL1 (0.42) EPHX2BCHEACHEBACE1
SCHEMBL375509 0.75 PARP1 (0.44) TACR1PDCD1CD274BCHEACHE
SCHEMBL374832 0.74 BCHE (0.60) EPHX2BCHEACHEBACE1KCNH2
SCHEMBL375548 0.74 EPHX1 (0.45) MEN1POLBKMT2ABCHEACHE
SCHEMBL3130662 0.74 MCL1 (0.53) TACR1HDAC3HDAC1HDAC2HDAC6
SCHEMBL375222 0.73 CARM1 (0.61) BCHEACHEBACE1MCHR1KCNN3
SCHEMBL27891441 0.72 CYP2A13 (0.58) MEN1KMT2AEPHX2CYP2C9CYP2C19
SCHEMBL22957856 0.72 HDAC3 (0.49) TACR1MEN1KMT2AEPHX2CYP2C9
SCHEMBL24710168 0.71 MAPT (0.58) TACR1MEN1KMT2AEPHX2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623898-B2 Glycine transporter inhibiting substances TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-07 US disclosed
EP-2409976-A1 GLYCINE TRANSPORTER INHIBITOR Taisho Pharmaceutical Co., Ltd. (JP) 2012-01-25 EP disclosed
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010414-A1 GLYCINE TRANSPORTER INHIBITING SUBSTANCES SLC18A2, SLC1A2, SLC6A1 TACR1 158/4885PDCD1 2523/4885CD274 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.